Who We Are
Solutions in IHC and Molecular Pathology
Our Company
Mexican Subsidiary of BIO SB Inc
Transnational company with presence in 90 countries
HQ Santa Barbara, California USA
+ 25 years of experience in research and development in pathology products
Our History
Bio SB Mexico is the Mexican subsidiary of Bio SB, a leader in the development and production of antibodies and detection systems for molecular pathology. We are proud to offer products of the highest quality that meet the most rigorous international standards.
Certifications
- ✓FDA QSR 21 CFR Part 820 cGMP
- ✓CE IVD
- ✓ISO13485:2016
Our Values
Quality
Products that meet the highest international standards
Innovation
Continuous development of new technologies and solutions
Service
Specialized technical support for our customers
Commitment
Dedication to our customers' success and patient health
Strategic Alliances
CDI - Cancer Diagnostics, Inc.
Through our alliance with Cancer Diagnostics, Inc. (CDI), a company founded in 1998 and a leader in the development and manufacturing of supplies for histology, cytology, and surgical pathology, we can offer our clients one of the industry's broadest portfolios of anatomic pathology products. CDI developed the first commercially available 7-dye color kit for marking tissue margins (CDI's® Tissue Marking Dyes) and currently has over 3,000 products in its line, serving more than 3,500 laboratories worldwide. This alliance allows us to provide reliable and cost-effective solutions for preanalytical, histopathology, H&E, and histology, complementing our portfolio with high-quality products that meet the industry's highest standards.
Zytomics
Our strategic alliance with ZYTOMICS allows us to offer specialized solutions in in situ hybridization (CISH and FISH) for cancer diagnosis. ZYTOMICS is the result of the unification of three established and longstanding European companies: Zytomed Systems, ZytoVision, and Diagomics, founded in 2021. This company is a leader in manufacturing and providing products and solutions for clinical cancer diagnostics, including reagents, automation, and analytics with a focus on in situ hybridization and next-generation sequencing diagnostics. ZYTOMICS holds IVDR certification (EU Regulation 2017/746) for a significant portion of its Class C product portfolio, ensuring regulatory compliance and world-class quality. With operations in Northern Germany, Austria, Switzerland, and Southern France, and an international distribution network covering more than 90 countries, this alliance allows us to provide our clients with access to advanced molecular diagnostic technologies with the highest standards of quality and reliability.